By Fineline Cube Shanghai Ark Biopharmaceutical Co., Ltd. announced that its independently developed first-in-class long-acting antiviral drug-Fc conjugate (AFC) AK0406 injection has received approval from China’s National Medical Products Administration (NMPA) to conduct clinical trials for influenza prevention, moving the candidate into Chinese clinical development on the back of a fully dosed Phase 1 study in Australia.
Regulatory Milestone
| Item | Detail |
|---|---|
| Company | Shanghai Ark Biopharmaceutical Co., Ltd. |
| Agency | NMPA (China) |
| Approval Type | Clinical trial approval |
| Drug | AK0406 injection — first-in-class long-acting antiviral drug-Fc conjugate (AFC) |
| Indication | Influenza prevention |
| Approval Date | 13 Aug 2026 |
| Prior Milestone | Australian HREC approval for Phase 1 trials (Feb 2026) |
Drug Profile – AK0406
- Modality: Innovative long-acting antiviral drug-Fc conjugate (AFC), independently developed by Ark Biopharmaceutical — precisely conjugating a highly potent antiviral small molecule with an antibody Fc fragment for extended circulation
- Application Scope: Long-acting pre- or post-exposure prophylaxis and potential therapeutic applications for influenza
- Target Need: Addresses clinical prevention needs during peak influenza seasons, where vaccines and short-acting antivirals leave coverage gaps
- Preclinical Profile: Broad-spectrum, highly potent, and long-acting antiviral properties, with comprehensive optimization across structural design, antiviral activity, pharmacokinetics, and manufacturing
Clinical Progress
| Program | Status |
|---|---|
| Australia Phase 1 | HREC approval Feb 2026; enrollment and dosing of all healthy-adult cohorts completed; currently in follow-up stage |
| China | NMPA clinical trial approval granted 13 Aug 2026; trial initiation expected |
Market Impact & Outlook
- First-in-Class Modality: The AFC architecture — extending small-molecule antivirals via Fc fusion — offers a differentiated approach in influenza prophylaxis, distinct from both seasonal vaccines and conventional antivirals.
- Prophylaxis Opportunity: A long-acting preventive could serve populations poorly covered by vaccination — the elderly, immunocompromised, and frontline healthcare workers during seasonal peaks.
- Parallel Development Tracks: With the Australian Phase 1 fully dosed and NMPA clearance secured, Ark Biopharmaceutical can pursue synchronized US-APAC-China development, strengthening its clinical dataset and partnering appeal.
- Next Steps: Follow-up results from the Australian cohorts and China trial design details were not disclosed.
Forward‑Looking Statements
This brief contains forward-looking statements regarding the clinical development and commercial potential of AK0406. Actual results may differ due to risks including clinical progress, safety outcomes, regulatory timelines, and competitive dynamics in influenza prevention.-Fineline Info & Tech